Rectal carcinoma

This phase 3 trial tests two different ways of using radiation before chemotherapy in people with stage III rectal cancer. One group gets a short course of radiation, the other gets standard chemoradiation, both followed by chemotherapy. The goal is to see if either approach can …

This phase II trial compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combos (FOLFOX or CAPOX) in 783 patients with locally advanced rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor, poten…

This early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …

This study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …

This phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…

This early phase trial tests a biological product mix designed to train the immune system to recognize and kill CEA-positive rectal cancer cells. The study involves 20 participants with early-stage rectal cancer (Stage 0 to IIA) who have not yet developed symptoms or metastasis. …

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This study tests whether surgeons can safely remove less tissue during surgery for upper rectal cancer after patients have received pre-surgery therapy. About 874 adults with locally advanced rectal cancer will be randomly assigned to either standard or reduced surgical margins. …

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to…

This early-phase trial tests a special PET scan that uses a radioactive tracer (64Cu-M5A) to highlight rectal cancer cells. The goal is to see if this scan can show tumor extent and response more accurately than standard imaging before and after chemotherapy and radiation. About …

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This study tests whether using telemedicine and remote monitoring can help people with advanced digestive cancers manage chemotherapy side effects at home, reducing the need for emergency room visits and hospital stays. About 750 patients and their caregivers will receive enhance…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This pilot study is testing whether regular MRI scans and blood tests can accurately track how rectal cancer responds to pre-surgery treatment. The goal is to develop a way to predict complete remission without needing surgery. Forty adults with locally advanced rectal cancer wil…

This study tested whether routine screening for four cancers (prostate, lung, colorectal, and ovarian) can lower the number of people who die from these diseases. Over 154,000 adults aged 55–74 joined the trial. Researchers compared cancer deaths between those who got screened an…

This study aimed to see if a blood test for cancer DNA (ctDNA) could help doctors decide which patients with stage 2 or 3 rectal cancer could safely avoid surgery and just be watched closely. It also looked at using the test to catch any cancer coming back early. However, the tri…

This study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …

This study planned to test if a 7-week program of aerobic and resistance exercise is feasible for people with locally advanced rectal cancer undergoing short-course radiotherapy. It aimed to recruit 30 patients and track how many joined, attended sessions, and stayed in the study…

This study looks at 266 adults with advanced rectal cancer who had radiation therapy followed by surgery. It compares standard chemoradiotherapy or short-course radiotherapy with a newer approach called total neoadjuvant treatment (TNT). The goal is to see which method leads to f…